AL amyloidosis and a critical, early diagnosis
Giampaolo Merlini, MD of Fondazione IRCCS Policlinico, San Matteo Pavia, Italy gives an overview of his talk on light-chain amyloidosis or AL amyloidosis at the 2016 European Multiple Myeloma Academy (EMMA) in Madrid, Spain. Although it is a rare disease, it represents 12–15% of patients with multiple myeloma (MM). Further, there is a condition called primary AL amyloidosis, where there is a small clone in the bone marrow that produces a protein (a light chain) with an abnormal confirmation and, due to this, the protein tends to aggregate; it can move to the kidney, heart and other organs where it causes progressive dysfunction and damage. It is possible to recover completely if intervention occurs in time; early diagnosis can change the outlook for the patient. Therefore, time is of the essence, as Dr Merlini explains, and it is vital for doctors to consider that their patient may be affected. Dr Merlini further highlights how this concerns the management of monoclonal gammopathy of undetermined significance (MGUS) patients. Dr Merlini further outlines how the diagnosis is made and that there are several proteins that can cause systemic amyloidosis. The second-most common one is produced by the liver; it is called transthyretin and can also affect the heart, in particular, in older men (known as wild-type ATTR amyloidosis). The available treatments now are extremely powerful, according to Dr Merlini. The treatment of AL amyloidosis is the most successful treatment of all types of amyloidosis because it is possible to suppress the production of the proteins that is causing the disease with drugs. Therefore, the production of light chains is stopped and this usually translates into very rapid improvement in the clinical condition of the patient. If the treatment is started early, organ dysfunction can be recovered and survival is extended; more than 30% of patients survive more than 10 years, which was unthinkable a few years ago. Further, the same drug that is used for treatment is also being developed in myeloma as the clone is very similar.
This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.
Видео AL amyloidosis and a critical, early diagnosis канала VJHemOnc – Video Journal of Hematological Oncology
This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.
Видео AL amyloidosis and a critical, early diagnosis канала VJHemOnc – Video Journal of Hematological Oncology
Показать
Комментарии отсутствуют
Информация о видео
4 октября 2016 г. 21:52:48
00:06:47
Другие видео канала
What is AL amyloidosis?AMYLOIDOSIS: Part 1: Definition, Historical aspects & Properties of AmyloidUpdate on diagnosis and treatment of AL amyloidosisAmyloidosis: diagnosis and stem cell transplantationLight Chain (AL) Amyloidosis: Treatment in 2020 and BeyondThe symptoms of amyloidosisManny’s Story | AL Amyloidosis Survivor | Patient TestimonialGreg Foster - Journey to Diagnosis: AL AmyloidosisThe Trouble with Diagnosing a Rare DiseaseCardiac Amyloidosis Interpretation Best PracticesDr Helen Lachmann – Management of complications and side-effects of treatmentOrgan Involvement in AL amyloidosisRichard Preston talking about his amyloidosis 23 March 2016AmyloidosisCardiac Amyloidosis: What Every Cardiologist Needs to Know - Mayo Clinic CV Grand RoundsAmyloidosis: What you need to know - Mayo ClinicDiana Williams' husband's battle against rare cancer, AmyloidosisCoping With the Loss of a SpouseWhat’s new in AA Amyloidosis in 2020 ?When A patient Asks to Die | House M.D.